Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant symptom relief trends.
The Hub of Australian Finance News
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant symptom relief trends.
Streamplay Studio (ASX:SP8) partners with Mobibox to launch Playstream cloud gaming service exclusively for Sri Lanka’s largest mobile operator.
Webjet Group Limited (ASX:WJL) rejects BGH’s unsolicited acquisition proposal, citing undervaluation and significant uncertainty.
Appen Limited (ASX:APX) reports 16% revenue growth in 2024 and outlines strategic plans for sustainable growth in 2025.
Simble Solutions Limited (ASX:SIS) reports significant 2024 operational achievements and strategic partnerships, driving growth and expansion.
Hastings Technology Metals (ASX:HAS) forms a 60:40 joint venture with Wyloo for the Yangibana Project, advancing development and reducing costs.
Tempest Minerals Limited (ASX:TEM) reports excellent initial metallurgical results for the Remorse Deposit at Yalgoo Project.
HITIQ Limited (ASX:HIQ) launches a non-renounceable entitlement issue aiming to raise up to $2.92 million to expand manufacturing and USA operations.
Chimeric Therapeutics (ASX:CHM) reports that two of three patients achieved complete response in its ADVENT-AML Phase 1B clinical trial.
IAG (ASX:IAG) enters a $1.35 billion strategic alliance with RAC to expand insurance services in Western Australia.